Immunotherapy prototype Mark 3.0 model in primary liver cancer: adding locoregional stereotactic therapy and prognostic factors classification management

Immunotherapy prototype Mark 3.0 model in primary liver cancer: adding locoregional stereotactic therapy and prognostic factors classification management

Immune checkpoint inhibitors (ICIs) like programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor have shown considerable efficacy in several important cancers including primary liver cancer (PLC) like hepatocellular carcinoma and cholangiocarcinoma. However, only some patients wit...

Full description

Bibliographic Details
Main Authors: Yang Xu, Zhang Nan, Song Yang, Yang Xiaobo, Sang Xinting, Zhao Haitao
Format: Article
Language:English
Published: De Gruyter 2023-01-01
Series:Medical Review
Subjects:
hepatocellular carcinoma
immune checkpoint inhibitors
primary liver cancer
prognostic factors
programmed cell death-1
stereotactic therapy
Online Access:https://doi.org/10.1515/mr-2022-0045

Internet

https://doi.org/10.1515/mr-2022-0045

Similar Items